| Schedule of antidilutive securities excluded from computation of earnings per share | |
| | | |
| | |
| | |
For
the Years Ended
December 31, | |
| | |
2025 | | |
2024 | |
| Basic and Diluted
Loss Per Share: | |
| | | |
| | |
| Numerator: | |
| | | |
| | |
| Net
loss from continuing operations | |
$ | (352,166 | ) | |
$ | (156,838 | ) |
| Net
loss from discontinued operations | |
| (4,082 | ) | |
| (9,540 | ) |
| Net
loss | |
$ | (356,248 | ) | |
$ | (166,378 | ) |
| Denominator: | |
| | | |
| | |
| Weighted
average common shares outstanding, basic and diluted | |
| 101,358,304 | | |
| 100,690,000 | |
| | |
| | | |
| | |
| Basic
and diluted net loss per share from continuing operations | |
$ | (0.00 | ) | |
$ | (0.00 | ) |
| Basic
and diluted net loss per share from discontinued operations | |
$ | (0.00 | ) | |
$ | (0.00 | ) |
| Basic
and diluted net loss per share | |
$ | (0.00 | ) | |
$ | (0.00 | ) |